Gemcitabine and capecitabine in previously anthracycline-treated metastatic breast cancer: A multicenter phase II study (SOLTI 0301 trial)

Annals of Oncology

Volumn 21, Issue 7, 2009, Pages 1442-1447

  Ciruelos, E M ^a   Corte J ^b   Cortes Funes H ^a   Mayordomo, J I ^c   Bermejo, B ^d   Ojeda, B ^e   Garcia E ^f   Rodriguez C A ^g   Munoz M ^h   Gomez P ^b   Manso, L ^a   Andres R ^c   Lluch, A ^d   Saura, C ^b   Mendiola, C ^a   Baselga, J ^b  

^a HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^b HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO LOZANO BLESA   (Spain)

^d HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^e HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^f HOSPITAL MORALES MESEGUER   (Spain)

^g HOSPITAL UNIVERSITARIO DE SALAMANCA   (Spain)

^h HOSPITAL CLÍNIC   (Spain)

Author keywords

Breast cancer (advanced); Capecitabine; Gemcitabine; Phase II trial

Indexed keywords

ANTHRACYCLINE; CAPECITABINE; GEMCITABINE;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLEEDING; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG WITHDRAWAL; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HUMAN; HYPERTRANSAMINASEMIA; LIVER DISEASE; LIVER TOXICITY; MAJOR CLINICAL STUDY; METASTASIS POTENTIAL; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; OVERALL SURVIVAL; PATIENT COMPLIANCE; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SKIN DISEASE; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VOMITING;

EID: 77954266279     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp536     Document Type: Article

References (30)

1. O'Shaughnessy JA, Blum J, Moiseyenko V et al. Randomized, open-label, phase II trial of oral capecitabine (Xeloda) versus a reference arm of intravenous CMF (cyclophosphamide, methotrexate and 5-fluorouracil) as first-line therapy for advanced/metastatic breast cancer. Ann Oncol 2001; 12: 1247-1254.
2. Bajetta E, Procopio G, Celio L et al. Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005; 23: 2155-2161.
3. Ershler WB. Capecitabine monotherapy: safe and effective treatment for metastatic breast cancer. Oncologist 2006; 11: 325-335.
4. Carmichael J, Possinger K, Philip P et al. Difluorodeoxycytidine (gemcitabine): a phase II study in patients with advanced breast cancer. J Clin Oncol 1995; 13: 2731-2736.
5. Blackstein M, Vogel CL, Ambinder R et al. Phase II study of gemcitabine in patients with metastatic breast cancer. Eur J Cancer 1997; 33: S149.
6. Spielman M, Kalla S, Llombart-Cussac A et al. Single-agent gemcitabine is active in previously treated metastatic breast cancer. Oncology 2001; 60: 303-307.
7. Albain KS, Nag SM, Calderillo-Ruiz G et al. Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008; 26(24): 3950-3957.
8. Vici P, Giotta F, Di Lauro L et al. Multicenter phase II trial of first-line docetaxel/gemcitabine in advanced breast cancer pretreated with adjuvant anthracyclines. Anticancer Res 2009; 29(5): 1841-1845.
9. Chan S, Romieu G, Huober J et al. Phase III study of gemcitabine plus docetaxel compared with capecitabine plus docetaxel for anthracycline-pretreated patients with metastatic breast cancer. J Clin Oncol 2009; 27(11): 1753-1760.
10. Roy V, LaPlant BR, Gross GG et al. Phase II trial of weekly nab-paclitaxel (Abraxane) in combination with gemcitabine in patients with metastatic breast cancer (N0531). Ann Oncol 2009; 20(3): 449-453.
11. Sawada N, Fujimoto-Ouchi K, Ishikawa T et al. Antitumor activity of combination therapy with capecitabine plus vinorelbine, and capecitabine plus gemcitabine in human tumor xenograft models. Proc Am Assoc Cancer Res 2002; 43: (Abstr 5388).
12. Schilsky RL, Bertucci D, Vogelzang NJ et al. Dose-escalating study of capecitabine plus gemcitabine combination therapy in patients with advanced cancer. J Clin Oncol 2002; 20: 582-587.
13. Hess V, Salzberg M, Borner M et al. Combining capecitabine and gemcitabine in patients with advanced pancreatic carcinoma. A phase I/II trial. J Clin Oncol 2003; 21: 66-68.
14. Rini BI, Weinberg V, Small EJ. A phase I trial of fixed dose rate gemcitabine and capecitabine in metastatic renal cell carcinoma. Cancer 2005; 103: 553-558.
15. Santini D, Virzí V, Vincenzi B et al. A phase I trial of fixed dose rate gemcitabine plus capecitabine in metastatic cancer patients. Ann Oncol 2007; 18: 576-580.
16. Hong S, Young D, Heung C et al. A phase II study of capecitabine plus gemcitabine in patients with locally advanced or metastatic pancreatic patients. Cancer Chemother Pharmacol 2008; 62(5): 763-768.
17. Benekli M, Yildiz R, Uner A et al. Gemcitabine plus capecitabine combination in metastatic breast cancer patients previously treated with anthracyclines and taxanes. Oncology 2007; 72: 308-313.
18. Andres R, Mayordomo JI, Lara R et al. Gemcitabine/capecitabine in patients with metastatic breast cancer pretreated with anthracyclines and taxanes. Clin Breast Cancer 2005; 6: 158-162.
19. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216.
20. O'Shaughnessy J, Twelves C, Aapro M. Treatment for anthracycline-pretreated metastatic breast cancer. Oncologist 2002; 7 (Suppl 6): 4-12.
21. Batist G, Ramakrisnan G, Sekhar Rao C et al. Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in randomized, multicentric trial of metastatic breast cancer. J Clin Oncol 2001; 19(5): 1444-1454.
22. Lee SH, Lee J, Park J. Capecitabine monotherapy in patients with anthracycline and taxane-pretreated metastatic breast cancer. Med Oncol 2004; 21: 223-231.
23. Zelek L, Cottu P, Tubiana-Hulin M et al. Phase II study of oxaliplatin and fluorouracil in taxane and anthracycline-pretreated breast cancer patients. J Clin Oncol 2002; 20: 2551-2558.
24. Laessig D, Stemmler HJ, Vehling-Kaiser U et al. Gemcitabine and carboplatin in intensively pretreated patients with metastatic breast cancer. Oncology 2007; 73: 407-414.
25. Ahn JB, Shim KY, Park JO et al. The efficacy and safety of docetaxel in patients with anthracycline pretreated metastatic breast cancer: a multicenter phase II study. J Korean Cancer Assoc 2000; 32: 235-243.
26. Michelotti A, Gennari A, Salvadori A et al. Paclitaxel and vinorelbine in anthracycline-pretreated breast cancer: a phase II study. Ann Oncol 1996; 7: 857-860.
27. Awada A, Albanell J, Canney PA et al. Bortezomib/docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer: a phase 1/11 dose-escalation study. Br J Cancer 2008; 98(9): 1500-1507.
28. O'Shaughnessy J, Miles D, Vukelja S et al. Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002; 20: 2812-2823.
29. Hennessy BT, Gauthier AM, Michaud LB et al. Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M.D. Anderson Cancer Center and a review of capecitabine toxicity in the literature. Ann Oncol 2005; 16: 1289-1296.
30. Dent S, Messersmith H, Trudeau M. Gemcitabine in the management of metastatic breast cancer: a systematic review. Breast Cancer Res Treat 2008; 108: 319-331.